METHOD FOR PREDICTION OF ONCOLOGICAL SURVIVAL RATE IN PATIENTS WITH NONMETASTATIC RENAL CELL CARCINOMA AFTER MALIGNANT NEPHRECTOMY OR PARTIAL NEPHRECTOMY Russian patent published in 2011 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: surgery material is subject to immunohistochemical and pathomorphological analysis. A Ki-67 antigen expression level and a mutant p53 oncogene expression level are determined. An average diameter of malignant cell nuclei, or the presence or the absence of nucleoli in the malignant cell nuclei are evaluated with the presence or the absence of the nucleoli in the malignant cell nuclei are stated at various magnifications, while cariometry is enabled with a certain minimum count of renal cell carcinoma cell nuclei. The predicted oncological survival rate is calculated by formula: Ymbv=1.83X₁+1.45X₂+1.18X₃, where Ymbv is a morphobiomolecular value; X₁ is a histological malignancy degree in points; X₂ is the Ki-67 expression level in points; X₃ is the p53 expression level in points. The histological malignancy degree is shown by the average diameter of the malignant cell nuclei, or the presence or the absence of the nucleoli in the malignant cell nuclei. The Ymbv value ≤6.29 shows a favourable prognosis for the oncological survival rate in the patients; the Ymbv value 6.82-8.92 provides a relatively favourable prognosis, while the Ymbv value 9.19-11.55 enables to state a relatively unfavourable prognosis, and an unfavourable prognosis is given by the Ymbv value > 11.55.

EFFECT: higher prediction accuracy.

5 dwg, 11 tbl, 2 ex